Helga Zoega

Last updated
Helga Zoega
HelgaZoega.jpg
Born1976 (age 4748)
Nationality Icelandic
Occupation(s) professor of Public Health at the Faculty of Medicine University of Iceland and Scientia A/Professor at the School of Population Health, University of New South Wales (UNSW) Sydney, Australia

Helga Zoega (born 1976) is a Professor of Public Health at the Faculty of Medicine, University of Iceland. She is a Scientia A/Professor of Pharmacoepidemiology at the Faculty of Medicine and Health, University of New South Wales (UNSW) Sydney, Australia. Her research focuses on the use and safety of medication among vulnerable populations, e.g. pregnant women and children. [1] [2]

Contents

Education

Zoega completed her BA in Political Science at the University of Iceland in 2002. In 2006, she completed an MA in Quantitative Methods in the Social Sciences at Columbia University. [3]

Zoega was the first to receive a doctorate in Public Health Sciences from the University of Iceland. [4] She defended her PhD thesis in 2011 [5] on psychotropic medication use among children and the effect of ADHD treatment on academic progress. [6] [7] Zoega was a postdoctoral fellow in Epidemiology at the Icahn School of Medicine at Mount Sinai in New York, 2011–2013.

Professional experience

Zoega joined the Faculty of Medicine, Centre of Public Health Sciences at the University of Iceland in 2012 and was promoted to Professor in 2016. [8] Previously, she was as a project manager for the Icelandic Prescription Medicines Register at the Directorate of Health (2006-2008). [3]

In 2017–2018, Zoega was a Visiting Professorial Fellow at UNSW Sydney, where she was awarded a Scientia Program Award to further her research in Pharmacoepidemiology (2018-2026). [9]

Zoega has served on several scientific and ethical committees, including the Icelandic Science and Technology Policy Council & Icelandic Science Board (2016–19), appointed by the Prime Minister of Iceland. [10] She played a pivotal role in the founding of the Nordic Pharmaco-Epidemiological Network (NorPEN), [11] for which she served on the Executive Committee (2013–18).

Zoega plays a leading role in large-scale international consortia in providing real-world evidence of medication safety and effectiveness during pregnancy, including InPreSS (International Pregnancy Safety Study), [12] SCAN-AED (Nordic Register-Based Study of Antiepileptics in Pregnancy), [13] and Co-OPT (Consortium for the Study Of Pregnancy Treatments). [14] Zoega has led commissioned research for the Australian Department of Health resulting in national drug policy changes.

Research

Zoega is a pharmacoepidemiologist with expertise in the use, safety and effectiveness of medications. Her research program is based on the use of "real-world data", i.e. large-scale electronic health and social data linked across sources in Australia, the Nordic countries, and the US. [4]

Zoega's research findings on pharmacotherapy during pregnancy have been published in JAMA, BMJ, JAMA Psychiatry, Annals of Internal Medicine, etc. Her work on stimulant treatment for ADHD includes multinational studies on treatment patterns, effects on academic progress and impact of relative-age, published in Pediatrics, Lancet Psychiatry, J Child Psychol Psychiatry, Acta Psychiatrica Scandinavica [15] and widely covered in media outlets (New York Times, Time Online, Reuters, ABC, US News, Boston Globe, etc.). [16] [17] [18] [19] [20]

Personal

Helga Zoega (b. 1976) divides her time between Sydney and Reykjavik. She has daughter and a son.

Selected work

Related Research Articles

<span class="mw-page-title-main">Modafinil</span> Eugeroic medication

Modafinil, sold under the brand name Provigil among others, is a wakefulness-promoting medication used primarily to treat narcolepsy. Modafinil is also approved for stimulating wakefulness in people with sleep apnea and shift work sleep disorder. It is taken by mouth. Modafinil is not approved by the US Food and Drug Administration (FDA) for use in people under age 17.

<span class="mw-page-title-main">Attention deficit hyperactivity disorder</span> Neurodevelopmental disorder

Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterised by executive dysfunction occasioning symptoms of inattention, hyperactivity, impulsivity and emotional dysregulation that are excessive and pervasive, impairing in multiple contexts, and otherwise age-inappropriate.

<span class="mw-page-title-main">Citalopram</span> SSRI antidepressant

Citalopram, sold under the brand name Celexa among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is used to treat major depressive disorder, obsessive compulsive disorder, panic disorder, and social phobia. The antidepressant effects may take one to four weeks to occur. It is typically taken orally. In some European countries, it is sometimes given intravenously to initiate treatment, before switching to the oral route of administration for continuation of treatment. It has also been used intravenously in other parts of the world in some other circumstances.

<span class="mw-page-title-main">Methylphenidate</span> Central nervous system stimulant

Methylphenidate, sold under the brand names Ritalin and Concerta among others, is a potent central nervous system (CNS) stimulant used medically to treat attention deficit hyperactivity disorder (ADHD) and, to a lesser extent, narcolepsy. It is a primary medication for ADHD ; it may be taken by mouth or applied to the skin, and different formulations have varying durations of effect, commonly ranging from 2–4 hours. For ADHD, the effectiveness of methylphenidate is comparable to atomoxetine but modestly lower than amphetamines.

Self-medication, sometime called do-it-yourself (DIY) medicine, is a human behavior in which an individual uses a substance or any exogenous influence to self-administer treatment for physical or psychological conditions, for example headaches or fatigue.

<span class="mw-page-title-main">Atomoxetine</span> Medication used to treat ADHD

Atomoxetine, sold under the brand name Strattera, is a medication used to treat attention deficit hyperactivity disorder (ADHD) and, to a lesser extent, cognitive disengagement syndrome. It may be used alone or along with psychostimulants. It is also used as a cognitive and executive functioning enhancer to improve self-motivation, persistence, attention, inhibition, and working memory. Use of atomoxetine is only recommended for those who are at least six years old. It is taken orally. Atomoxetine is a selective norepinephrine reuptake inhibitor and is believed to work by increasing norepinephrine and dopamine levels in the brain. The effectiveness of atomoxetine is comparable to the commonly prescribed stimulant medication methylphenidate.

<span class="mw-page-title-main">Dexmethylphenidate</span> CNS Stimulant

Dexmethylphenidate, sold under the brand name Focalin among others, is a potent central nervous system (CNS) stimulant used to treat attention deficit hyperactivity disorder (ADHD) in those over the age of five years. It is taken by mouth. The immediate release formulation lasts up to five hours while the extended release formulation lasts up to twelve hours. It is the more active enantiomer of methylphenidate.

<span class="mw-page-title-main">Bumetanide</span> A loop diuretic

Bumetanide, sold under the brand name Bumex among others, is a medication used to treat swelling and high blood pressure. This includes swelling as a result of heart failure, liver failure, or kidney problems. It may work for swelling when other medications have not. For high blood pressure it is not a preferred treatment. It is taken by mouth, or by injection into a vein or muscle. Effects generally begin within an hour and last for about six hours.

Peter Roger Breggin is an American psychiatrist and critic of shock treatment and psychiatric medication and COVID-19 response. In his books, he advocates replacing psychiatry's use of drugs and electroconvulsive therapy with psychotherapy, education, empathy, love, and broader human services.

Adult Attention Deficit Hyperactivity Disorder is the persistence of attention deficit hyperactivity disorder (ADHD) into adulthood. It is a neurodevelopmental disorder, meaning impairing symptoms must have been present in childhood except for when ADHD occurs after traumatic brain injury. Specifically, multiple symptoms must be present before the age of 12, according to DSM-5 diagnostic criteria. The cutoff age of 12 is a change from the previous requirement of symptom onset, which was before the age of 7 in the DSM-IV. This was done to add flexibility in the diagnosis of adults. ADHD was previously thought to be a childhood disorder that improved with age, but recent research has disproved this. Approximately two-thirds of childhood cases of ADHD continue into adulthood, with varying degrees of symptom severity that change over time and continue to affect individuals with symptoms ranging from minor inconveniences to impairments in daily functioning.

<span class="mw-page-title-main">Viloxazine</span> Medication used to treat ADHD

Viloxazine, sold under the brand name Qelbree and formerly as Vivalan among others, is a selective norepinephrine reuptake inhibitor medication which is used in the treatment of attention deficit hyperactivity disorder (ADHD) in children and adults. It was marketed for almost 30 years as an antidepressant for the treatment of depression before being discontinued and subsequently repurposed as a treatment for ADHD. Viloxazine is taken orally. It was used as an antidepressant in an immediate-release form and is used in ADHD in an extended-release form.

<span class="mw-page-title-main">Biperiden</span> Group of stereoisomers

Biperiden, sold under the brand name Akineton among others, is a medication used to treat Parkinson disease, certain drug-induced movement disorders and Tourette Syndrome. It is not recommended for tardive dyskinesias. It is taken by mouth, injection into a vein, or muscle.

<span class="mw-page-title-main">Guanfacine</span> Medication used for high blood pressure and ADHD

Guanfacine, sold under the brand name Tenex (immediate-release) and Intuniv (extended-release) among others, is an oral alpha-2a agonist medication used to treat attention deficit hyperactivity disorder (ADHD) and high blood pressure. Guanfacine is FDA-approved for monotherapy treatment of ADHD, as well as being used for augmentation of other treatments, such as stimulants. Guanfacine is also used off-label to treat tic disorders, anxiety disorders, and post-traumatic stress disorder (PTSD).

<span class="mw-page-title-main">Attention deficit hyperactivity disorder controversies</span> Controversies surrounding the topic of ADHDs nature, diagnosis, and treatment

Despite the scientifically well-established nature of attention deficit hyperactivity disorder (ADHD), its diagnosis, and its treatment, each of these has been controversial since the 1970s. The controversies involve clinicians, teachers, policymakers, parents, and the media. Positions range from the view that ADHD is within the normal range of behavior to the hypothesis that ADHD is a genetic condition. Other areas of controversy include the use of stimulant medications in children, the method of diagnosis, and the possibility of overdiagnosis. In 2009, the National Institute for Health and Care Excellence, while acknowledging the controversy, stated that the current treatments and methods of diagnosis are based on the dominant view of the academic literature.

Tourette syndrome is an inherited neurodevelopmental disorder that begins in childhood or adolescence, characterized by the presence of motor and phonic tics. The management of Tourette syndrome has the goal of managing symptoms to achieve optimum functioning, rather than eliminating symptoms; not all persons with Tourette's require treatment, and there is no cure or universally effective medication. Explanation and reassurance alone are often sufficient treatment; education is an important part of any treatment plan.

Attention deficit hyperactivity disorder management options are evidence-based practices with established treatment efficacy for ADHD.

Pharmacoepidemiology is the study of the uses and effects of drugs in well-defined populations.

<span class="mw-page-title-main">Vilazodone</span> Antidepressant medication

Vilazodone, sold under the brand name Viibryd among others, is a medication used to treat major depressive disorder. It is classified as a serotonin modulator and is taken by mouth.

Women should speak to their doctor or healthcare professional before starting or stopping any medications while pregnant. Non-essential drugs and medications should be avoided while pregnant. Tobacco, alcohol, marijuana, and illicit drug use while pregnant may be dangerous for the unborn baby and may lead to severe health problems and/or birth defects. Even small amounts of alcohol, tobacco, and marijuana have not been proven to be safe when taken while pregnant. In some cases, for example, if the mother has epilepsy or diabetes, the risk of stopping a medication may be worse than risks associated with taking the medication while pregnant. The mother's healthcare professional will help make these decisions about the safest way to protect the health of both the mother and unborn child. In addition to medications and substances, some dietary supplements are important for a healthy pregnancy, however, others may cause harm to the unborn child.

Attention-Deficit/Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder characterized by difficulty focusing attention, hyperactivity, and impulsive behavior. Treatments generally involve behavioral therapy and/or medications. ADHD is estimated to affect about 6 to 7 percent of people aged 18 and under when diagnosed via the DSM-IV criteria. When diagnosed via the ICD-10 criteria, hyperkinetic disorder gives rates between 1 and 2 percent in this age group.

References

  1. Háskóli Íslands. Áhrif lyfjanotkunar á meðgöngu. Helga Zoéga, prófessor í lýðheilsuvísindum. Retrieved March 23, 2020.
  2. University of Iceland. Connections between pregnancy complications and ADHD in children. Retrieved March 23, 2020.
  3. 1 2 "University of Iceland. Professor of Public Health".
  4. 1 2 "Vísindavefurinn. (2018). Hvað hefur vísindamaðurinn Helga Zoega rannsakað?".
  5. Doktorsritgerð 2011: Psychotropic Drug Use among Children A Comparison of ADHD Drug Use in the Nordic Countries and the Effect of ADHD Drug Treatment on Academic Progress.
  6. Mbl.is. (2012, June 25). Tengsl milli einkunna og lyfjameðferðar við ADHD. Retrieved March 23, 2020.
  7. Skrá um doktorsritgerðir Íslendinga. Helga Zoega. Retrieved March 23, 2020.
  8. Háskóli Íslands. (2016). Hátt í fimmtíu fræðimenn fá framgang í starfi. Retrieved March 23, 2020.
  9. UNSW Sydney. 2018 Scientia Fellowships drive equity, diversity and excellence in research. Retrieved March 23, 2020.
  10. mbl.is. (2015, December 23).Ráðherra skipar vísinda- og tækniráð. Retrieved March 23, 2020.
  11. Nordic Pharmaco-Epidemiological Network (NorPEN). . Retrieved March 23, 2020.
  12. Harvard Program on Perinatal and Pediatric Pharmacoepidemiology. Collaborators. The International Pregnancy Safety Study (InPreSS) Consortium. Retrieved March 23, 2020.
  13. Bergen Epilepsy Research Group. SCAN-AED: Nordic register-based study of antiepileptic drugs in pregnancy.Retrieved March 23, 2020.
  14. The University of Edinburgh. Co-OPT: consortium for the study of pregnancy treatments. Retrieved March 23, 2020.
  15. Google Scholar. Helga Zoega. Retrieved March 23, 2020.
  16. Anahad O’Connor. (2012, November 20). Younger Students More Likely to Get A.D.H.D. Drugs. New York Times. Retrieved March 23, 2020.
  17. Deborah Kotz. (2012, November 23). Youngest kids in class more likely to get ADHD drugs, study finds. Boston Globe. Retrieved March 23, 2020.
  18. Lara Salahi. (2012, June 25). Earlier May Be Better for ADHD Meds in Kids. ABC News. Retrieved March 23, 2020.
  19. Angus Chen. (2016, March 10). Youngest Kids In Class At Higher Risk Of ADHD Diagnosis. NPR. Retrieved March 23, 2020.
  20. Huffington Post. (2016, May 23). Conclusive Proof ADHD Is Overdiagnosed. Retrieved March 23, 2020.